Thrombolex, Inc. - DVT Results with the Bashir™ Catheter.

Thrombolex, Inc. - DVT Results with the Bashir™ Catheter.

The BASHIR™ Endovascular Catheter (BEC) and the BASHIR™ Plus Endovascular Catheters (BASHIR™+ 10, BASHIR™+20, BASHIR™+30, BASHIR™+40) are hybrid devices that enable both mechanical and pharmacological treatment through use of an expandable infusion basket with... - October 14, 2021

Thrombolex, Inc. – Interim Results of NIH-Funded RESCUE Trial

Thrombolex, Inc. – Interim Results of NIH-Funded RESCUE Trial

Thrombolex, Inc. – BASHIR™ Endovascular Catheter Shows Marked Reduction in RV/LV Ratio and Thrombus Burden in Patients with Acute Intermediate-Risk PE - October 06, 2021

Thrombolex, Inc. – RESCUE Trial Interim Data Presented at VIVA

Thrombolex, Inc. – RESCUE Trial Interim Data Presented at VIVA

Thrombolex, Inc. continues to enroll in the pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE). This trial is conducted using the BASHIR™ and BASHIR™ S-B Endovascular Catheters (BEC) under an Investigational Device Exemption (IDE) from the... - September 29, 2021

THROMBOLEX, Inc. – Attendance at VIVA & VEINS

THROMBOLEX, Inc. – Attendance at VIVA & VEINS

THROMBOLEX, Inc. will be attending the VEINS Conference (Booth T8) and VIVA Physicians Conference (Booth #502) in Las Vegas, NV October 3-7. - September 16, 2021

THROMBOLEX™ Inc. First Patient Enrolled in the RESCUE Trial for Treatment of Acute Submassive Pulmonary Embolism

THROMBOLEX™ Inc. has announced that it has enrolled the first patient in its pivotal RESCUE trial for the treatment of patients with acute submassive pulmonary embolism (PE) using the BASHIR® Endovascular Catheter, under an Investigational Device Exemption (IDE) from the FDA. RESCUE is a... - August 06, 2020

THROMBOLEX™ Inc. Receives $3 million Small Business Innovation Research (SBIR) Grant from the NIH to Fund the RESCUE Trial

THROMBOLEX™ Inc. Receives $3 million Small Business Innovation Research (SBIR) Grant from the NIH to Fund the RESCUE Trial

Thrombolex™ Inc. has announced that it was awarded a $3 million Small Business Innovation Research (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI) section of the NIH to fund their pivotal RESCUE trial under an IDE for the treatment of up to 125 patients with acute,... - July 07, 2020

Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism

Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism

Thrombolex Bashir® Endovascular Catheter First-In-Man (FIM) Trial for Acute Pulmonary Embolism Confirms Early Safety and Feasibility and Impressive Reduction of Clot Burden - Results of FIM Trial presented at American Venous Forum (AVF) Annual Meeting - March 05, 2020

Thrombolex is Honored by Receiving Temple University’s Prestigious President’s Spin-Out Award

Thrombolex is Honored by Receiving Temple University’s Prestigious President’s Spin-Out Award

Temple University President, Richard Englert, and Vice President for Research, Michele Masucci, gathered colleagues to honor the University’s top inventors, and distinguished researchers at the third annual President’s Innovation Award Gala. Fueled by more than $279 million in annual... - February 19, 2020

Thrombolex, Inc. Announces First Patient Enrolled in Early Feasibility & Safety Study Using the Bashir™ Endovascular Catheter for Pulmonary Embolism

Thrombolex, Inc. Announces First Patient Enrolled in Early Feasibility & Safety Study Using the Bashir™ Endovascular Catheter for Pulmonary Embolism

Thrombolex, Inc. today announced the enrollment of the first patient in their Early Feasibility and Safety Study, investigating the Bashir™ Endovascular Catheter for the treatment of submassive pulmonary embolism (PE). The device was designed to quickly and safely dissolve thrombus and... - July 29, 2019

Press Releases 1 - 9 of 9